Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16M Delta purEK)

Citation
Dl. Hoover et al., Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16M Delta purEK), INFEC IMMUN, 67(11), 1999, pp. 5877-5884
Citations number
39
Categorie Soggetti
Immunology
Journal title
INFECTION AND IMMUNITY
ISSN journal
00199567 → ACNP
Volume
67
Issue
11
Year of publication
1999
Pages
5877 - 5884
Database
ISI
SICI code
0019-9567(199911)67:11<5877:POMABB>2.0.ZU;2-7
Abstract
Human brucellosis can be acquired from infected animal tissues by ingestion , inhalation, or contamination of the conjunctiva or traumatized skin by in fected animal products. A vaccine to protect humans from occupational expos ure or from zoonotic infection in areas where the disease is endemic would reduce an important cause of morbidity worldwide. Vaccines currently used i n animals are unsuitable for human use. We tested a live, attenuated, purin e-auxotrophic mutant strain of Brucella melitensis, WR201, for its ability to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with B. melitensis 16M. Mice inoculated intraperitone ally with WR201 made serum antibody to lipopolysaccharide and non-O-polysac charide antigens. Splenocytes from immunized animals released interleukin-2 (IL-2), gamma interferon, and IL-10 when cultured with Brucella antigens. Immunization led to protection from disseminated infection but had only a s light effect on clearance of the challenge inoculum from the lungs. These s tudies suggest that WR201 should be further investigated as a vaccine to pr event human brucellosis.